Gene · 8784
Papers4,557
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
561 to 580 of 4,557
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MetaTiME integrates single-cell gene expression to characterize the meta-components of the tumor immune microenvironment. | Nat Commun | 2023 | 37149682 | PubTator, text mining | PubMed |
| Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer. | Front Endocrinol (Lausanne) | 2023 | 37143720 | PubTator, text mining | PubMed |
| A novel signature based on cancer-associated fibroblast genes to predict prognosis, immune feature, and therapeutic response in breast cancer. | Aging (Albany NY) | 2023 | 37142271 | PubTator, text mining | PubMed |
| Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies. | Front Immunol | 2023 | 37138880 | PubTator, text mining | PubMed |
| Comprehensive analysis of prognostic value and immunotherapy prospect of brain cytoplasmic RNA1 in hepatocellular carcinoma. | World J Gastrointest Oncol | 2023 | 37123057 | PubTator, text mining | PubMed |
| ZAP70 interaction with 13 mRNAs as a potential immunotherapeutic target for endometrial cancer. | Oncol Lett | 2023 | 37123018 | PubTator, text mining | PubMed |
| Wiskott-Aldrich syndrome gene as a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma. | Front Immunol | 2023 | 37122750 | PubTator, text mining | PubMed |
| Comprehensive Analysis of NABP2 as a Prognostic Biomarker and Its Correlation with Immune Infiltration in Hepatocellular Carcinoma. | J Inflamm Res | 2023 | 37113629 | PubTator, text mining | PubMed |
| Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN. | Hepatol Commun | 2023 | 37102765 | PubTator, text mining | PubMed |
| Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells. | Adv Sci (Weinh) | 2023 | 37097643 | PubTator, text mining | PubMed |
| Novel prognostic features and personalized treatment strategies for mitochondria-related genes in glioma patients. | Front Endocrinol (Lausanne) | 2023 | 37091853 | PubTator, text mining | PubMed |
| Predictive role of blood-based indicators in neuromyelitis optica spectrum disorders. | Front Neurosci | 2023 | 37090792 | PubTator, text mining | PubMed |
| Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future. | Front Immunol | 2023 | 37090741 | PubTator, text mining | PubMed |
| Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy. | Adv Sci (Weinh) | 2023 | 37088780 | PubTator, text mining | PubMed |
| Development of an endoplasmic reticulum stress-related signature with potential implications in prognosis and immunotherapy in head and neck squamous cell carcinoma. | Diagn Pathol | 2023 | 37087456 | PubTator, text mining | PubMed |
| Dissecting the roles and clinical potential of YY1 in the tumor microenvironment. | Front Oncol | 2023 | 37081988 | PubTator, text mining | PubMed |
| Identification of a prognostic biomarker predicting biochemical recurrence and construction of a novel nomogram for prostate cancer. | Front Oncol | 2023 | 37077837 | PubTator, text mining | PubMed |
| Advances in computational frameworks in the fight against TB: The way forward. | Front Pharmacol | 2023 | 37077815 | PubTator, text mining | PubMed |
| Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers. | Mol Cancer | 2023 | 37072770 | PubTator, text mining | PubMed |
Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3. | Front Oncol | 2023 | 37064132 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8784/papers?page=29